2. Academic Validation
  3. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants

  • J Biomed Sci. 2022 Jul 7;29(1):49. doi: 10.1186/s12929-022-00830-1.
I-Jung Lee 1 2,  Cheng-Pu Sun  # 1,  Ping-Yi Wu  # 1,  Yu-Hua Lan 1,  I-Hsuan Wang 1,  Wen-Chun Liu 3,  Joyce Pei-Yi Yuan 3,  Yu-Wei Chang 3,  Sheng-Che Tseng 1,  Szu-I Tsung 1 2,  Yu-Chi Chou 3,  Monika Kumari 4,  Yin-Shiou Lin 3,  Hui-Feng Chen 3,  Tsung-Yen Chen 3,  Chih-Chao Lin 3,  Chi-Wen Chiu 1 5,  Chung-Hsuan Hsieh 1 5,  Cheng-Ying Chuang 1,  Chao-Min Cheng 3,  Hsiu-Ting Lin 4,  Wan-Yu Chen 4,  Fu-Fei Hsu 3 4,  Ming-Hsiang Hong 3 4,  Chun-Che Liao 1,  Chih-Shin Chang 3,  Jian-Jong Liang 1,  Hsiu-Hua Ma 6,  Ming-Tsai Chiang 1,  Hsin-Ni Liao 1,  Hui-Ying Ko 1,  Liang-Yu Chen 1,  Yi-An Ko 3,  Pei-Yu Yu 7,  Tzu-Jing Yang 7,  Po-Cheng Chiang 3,  Shang-Te Hsu 7,  Yi-Ling Lin 1 3,  Chong-Chou Lee 3,  Han-Chung Wu 3 4,  Mi-Hua Tao 8 9 10 11
Affiliations

Affiliations

  • 1 Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
  • 2 Graduate Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • 3 Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
  • 4 Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan.
  • 5 Department of Clinical Laboratory Science and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
  • 6 Genomics Research Center, Academia Sinica, Taipei, Taiwan.
  • 7 Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.
  • 8 Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan. [email protected].
  • 9 Graduate Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan. [email protected].
  • 10 Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan. [email protected].
  • 11 Department of Clinical Laboratory Science and Medical Biotechnology, National Taiwan University, Taipei, Taiwan. [email protected].
  • # Contributed equally.
PMID: 35799178 DOI: 10.1186/s12929-022-00830-1
Abstract

Background: With the continuous emergence of new SARS-CoV-2 variants that feature increased transmission and immune escape, there is an urgent demand for a better vaccine design that will provide broader neutralizing efficacy.

Methods: We report an mRNA-based vaccine using an engineered "hybrid" receptor binding domain (RBD) that contains all 16 point-mutations shown in the currently prevailing Omicron and Delta variants.

Results: A booster dose of hybrid vaccine in mice previously immunized with wild-type RBD vaccine induced high titers of broadly neutralizing Antibodies against all tested SARS-CoV-2 variants of concern (VOCs). In naïve mice, hybrid vaccine generated strong Omicron-specific neutralizing Antibodies as well as low but significant titers against other VOCs. Hybrid vaccine also elicited CD8+/IFN-γ+ T cell responses against a conserved T cell epitope present in wild type and all VOCs.

Conclusions: These results demonstrate that inclusion of different antigenic mutations from various SARS-CoV-2 variants is a feasible approach to develop cross-protective vaccines.

Keywords

Booster dose; COVID-19; Cross-protectivity; Hybrid vaccine; Next generation vaccine; Omicron vaccine; SARS-CoV-2; Variants of concern; mRNA vaccine.

Figures
Products